| Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders AC Rawstron, A Orfao, M Beksac, L Bezdickova, R Brooimans, H Bumbea, ... haematologica 93 (3), 431-438, 2008 | 654 | 2008 |
| Differences in risk factors for breast cancer molecular subtypes in a population-based study XR Yang, ME Sherman, DL Rimm, J Lissowska, LA Brinton, B Peplonska, ... Cancer Epidemiology Biomarkers & Prevention 16 (3), 439-443, 2007 | 622 | 2007 |
| Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network E Hoster, A Rosenwald, F Berger, HW Bernd, S Hartmann, ... Journal of Clinical Oncology 34 (12), 1386-1394, 2016 | 366 | 2016 |
| CCND2 rearrangements are the most frequent genetic events in cyclin D1− mantle cell lymphoma I Salaverria, C Royo, A Carvajal-Cuenca, G Clot, A Navarro, A Valera, ... Blood, The Journal of the American Society of Hematology 121 (8), 1394-1402, 2013 | 235 | 2013 |
| A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma I Salaverria, I Martin-Guerrero, R Wagener, M Kreuz, CW Kohler, J Richter, ... Blood, The Journal of the American Society of Hematology 123 (8), 1187-1198, 2014 | 214 | 2014 |
| Ki-67 as a prognostic marker in mantle cell lymphoma—consensus guidelines of the pathology panel of the European MCL Network W Klapper, E Hoster, O Determann, I Oschlies, J van der Laak, F Berger, ... Journal of hematopathology 2, 103-111, 2009 | 193 | 2009 |
| Established breast cancer risk factors by clinically important tumour characteristics M Garcia-Closas, LA Brinton, J Lissowska, N Chatterjee, B Peplonska, ... British journal of cancer 95 (1), 123-129, 2006 | 170 | 2006 |
| The whole-genome landscape of Burkitt lymphoma subtypes RI Panea, CL Love, JR Shingleton, A Reddy, JA Bailey, AM Moormann, ... Blood, The Journal of the American Society of Hematology 134 (19), 1598-1607, 2019 | 145 | 2019 |
| Expression of TP53 is associated with outcome of MCL independent of MIPI and Ki-67 in trials of the European-MCL Network SM Aukema, E Hoster, A Rosenwald, D Canoni, MH Delfau-Larue, ... Blood, blood-2017-07-797019, 2017 | 142 | 2017 |
| CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1− mantle cell lymphoma D Martín-Garcia, A Navarro, R Valdés-Mas, G Clot, J Gutiérrez-Abril, ... Blood, The Journal of the American Society of Hematology 133 (9), 940-951, 2019 | 101 | 2019 |
| The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma R Wagener, J Seufert, F Raimondi, S Bens, K Kleinheinz, I Nagel, ... Blood, The Journal of the American Society of Hematology 133 (9), 962-966, 2019 | 94 | 2019 |
| The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma RG Esteve-Arenys A, Valero JG, Chamorro-Jorganes A, Gonzalez D, Rodriguez V ... Oncogene 100 (10.1038/s41388-017-0111-1.), 2018 | 87* | 2018 |
| Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: A population‐based analysis ME Sherman, DL Rimm, XR Yang, N Chatterjee, LA Brinton, J Lissowska, ... International journal of cancer 121 (5), 1079-1085, 2007 | 66 | 2007 |
| A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration. G Rymkiewicz, B Grygalewicz, M Chechlinska, K Blachnio, ... Modern Pathology 31 (doi:10.1038/modpathol.2017.186), 1-12, 2018 | 59 | 2018 |
| The 11q-gain/loss aberration occurs recurrently in MYC-negative Burkitt-like lymphoma with 11q aberration, as well as MYC-positive Burkitt lymphoma and MYC-positive high-grade … B Grygalewicz, R Woroniecka, G Rymkiewicz, J Rygier, K Borkowska, ... American Journal of Clinical Pathology 149 (1), 17-28, 2018 | 56 | 2018 |
| Partial trisomy 11, dup (11)(q23q13), as a defect characterizing lymphomas with Burkitt pathomorphology without MYC gene rearrangement B Pienkowska-Grela, G Rymkiewicz, B Grygalewicz, R Woroniecka, ... Medical Oncology 28 (4), 1589-1595, 2011 | 55 | 2011 |
| Molecular Mechanisms in Malignant Lymphoma Network Project. Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group. A recurrent 11q aberration pattern characterizes a subset of … I Salaverria, I Martin-Guerrero, R Wagener, M Kreuz, CW Kohler, J Richter, ... Blood 123 (8), 1187-98, 2014 | 49 | 2014 |
| Characteristics of T-cell large granular lymphocyte proliferations associated with neutropenia and inflammatory arthropathy M Prochorec-Sobieszek, G Rymkiewicz, H Makuch-Łasica, M Majewski, ... Arthritis Research & Therapy 10, 1-12, 2008 | 42 | 2008 |
| Cytogenetic and flow cytometry evaluation of Richter syndrome reveals MYC, CDKN2A, IGH alterations with loss of CD52, CD62L and increase of CD71 antigen expression as the most … R Woroniecka, G Rymkiewicz, B Grygalewicz, K Błachnio, J Rygier, ... American journal of clinical pathology 143 (1), 25-35, 2015 | 41 | 2015 |
| Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network. RA Rauert-Wunderlich H, Mottok A, Scott DW, Rimsza LM, Ott G, Klapper W ... Br J Haematol. 2018, 2018 | 34 | 2018 |
Martin DreylingProfessor of Medicine, University of Munich在 med.uni-muenchen.de 的电子邮件经过验证
